4th Annual Biomarker and Companion Diagnostics Conference
07 February 2019
The 4th Annual Biomarker and Companion Diagnostics Conference scheduled to be held on 7th-8th February 2019 in San Diego, CA would address the gaps between early stage biomarker development and the commercialization stage of biomarkers. Regarding commercialization of biomarkers, leading industry and academic experts would share their case studies focusing on advancements in companion diagnostics area.
Click here to view post-show report of The 3rd Annual Biomarker Conference (2018)
Clinical biomarker identification and qualification | Biomarkers and personalized medicine | Assay development and validation | NGS and novel technologies in biomarker discovery | Commercialization of biomarkers in therapeutic and CDx applications
30+ experts from academia and industry presenting their current work in Biomarkers
Latest updates on regulatory guidelines and approvals | Case studies from experts who have successfully created and developed a biomarker | Facilitated networking sessions to ensure quality interactions | One on one query handling by biomarker experts |Opportunity to develop long-lasting business relationships and networking opportunities with senior peers.
Who Should Attend
Researchers, scientists, clinicians, academicians and professionals from
Pharmaceutical companies |Bio-pharma companies |Universities and Research institutes
Biomarker discovery/development | Translational research | Clinical Biomarker | Biomarkers in IO and Neurological disorders | Imaging Biomarkers | Pathology | Companion Diagnostics
Myriad RBM, Inc is a CLIA certified, multiplexed immunoassay testing laboratory that solves complex drug development challenges with innovative biomarker services. Myriad RBM’s internally developed and manufactured immunoassay kits based on Multi-Analyte Profiling (MAP) and ultrasensitive Single-Molecule Array (SimoaTM) technology, provide reproducible and quantitative data for hundreds of human proteins.